Bivariate Analysis for Use of GLP-1a or SGLT-2i
| Characteristic | Patients on GLP-1a or SGLT-2i (%) | Patients Not on GLP-1a or SGLT-2i (%) | p-Value |
|---|---|---|---|
| Gender | 0.38 | ||
| Male | 748 (5.0) | 14272 (95.0) | |
| Female | 849 (5.2) | 15485 (94.8) | |
| Race | |||
| African American | 418 (3.3) | 12360 (96.7) | <0.05 |
| White | 1179 (6.3) | 17397 (93.7) | |
| Age strata | |||
| Age 40 – 49 | 249 (7.0) | 3317 (93.0) | <0.05 |
| Age 50 – 59 | 549 (7.1) | 7207 (92.9) | |
| Age 60 – 60 | 609 (5.3) | 10953 (94.7) | |
| Age 70 – 79 | 190 (2.2) | 8280 (97.8) | |
| Insurance | |||
| Commercial | 947 (59.7) | 12391 (42.0) | < 0.05 |
| Medicaid | 110 (6.9) | 2969 (10.1) | |
| Medicare | 529 (33.4) | 14165 (48.0) | |
| Income strata | |||
| Income < $27000 | 138 (3.1) | 4346 (96.6) | < 0.05 |
| Income $27000 – 44999 | 398 (4.3) | 8857 (95.7) | |
| Income $45000 – 65999 | 543 (5.7) | 9017 (94.3) | |
| Income > $66,000 | 512 (6.4) | 7, 452 (93.6) | |
| BMI strata | |||
| BMI < 18.5 | 0 (0.0) | 80 (100.0) | < 0.05 |
| BMI 18.5 – 24.9 | 41 (1.7) | 2309 (98.3) | |
| BMI 25.0 – 29.9 | 246 (3.3) | 7191 (96.7) | |
| BMI 30.0 – 39.9 | 834 (5.4) | 14540 (94.6) | |
| BMI 40.0 – 49.9 | 476 (7.8) | 5637 (92.2) | |
| HbA1c category | |||
| HbA1c < 7.0% | 383 (2.6) | 14367 (97.4) | <0.05 |
| HBbA1c 1,1 – 8.9% | 715 (6.8) | 9572 (93.2) | |
| HbA1c > 9.0% | 499 (8.1) | 5638 (91.9) | |
| CKD Stage | |||
| CKD Stage 1 (eGFR >90) | 751 (6.3) | 11183 (93.7) | < 0.05 |
| CKD Stage 2 (eGF 60 – 89) | 618 (4.8) | 12295 (95.2) | |
| CKD Stage 3a (eGFR 45 – 59) | 158 (4.4) | 3439 (95.6) | |
| CKD Stage 3b (eGFR 30 – 44) | 62 (3.5) | 1688 (96.5) | |
| CKD Stage 4 (eGFR 15 – 29) | 7 (1.1) | 646 (98.9) | |
| CKD Stage 5 (eGFR <15) | 1 (0.2) | 506 (99.8) | |
| Hypertension | 1281 (80.8) | 24001 (80.7) | 0.86 |
| ASCVD | 385 (24.1) | 9172 (30.8) | <0.05 |
| Current Cigarette Use | 192 (12.0) | 4993 (16.8) | <0.05 |
| Statin Use | 1120 (70.1) | 19471 (65.4) | <0.05 |
| Metformin Use | 1163 (72.8) | 18178 (61.1) | <0.05 |
| Insulin Use | 932 (58.4) | 12209 (41.0) | <0.05 |
Abbreviations: GLP-1a, glucagon-like peptide 1; SGLT-2i, sodium glucose cotransporter-2; BMI, body mass index; HbA1c, hemoglobin A1c; ASCVD, Atherosclerotic cardiovascular disease.